CorMedix’s (CRMD) “Outperform” Rating Reaffirmed at Oppenheimer

Oppenheimer reaffirmed their outperform rating on shares of CorMedix (NASDAQ:CRMD) in a research note issued to investors on Friday, MarketBeat Ratings reports. The firm currently has a $13.00 target price on the stock, down from their previous target price of $15.00.

CRMD has been the topic of several other reports. UBS Group set a $19.00 target price on CorMedix in a research report on Tuesday. Royal Bank Of Canada boosted their price target on CorMedix from $14.00 to $15.00 and gave the stock an “outperform” rating in a research report on Tuesday. Citigroup reiterated a “market outperform” rating on shares of CorMedix in a research report on Tuesday. Weiss Ratings cut CorMedix from a “hold (c+)” rating to a “hold (c)” rating in a research note on Tuesday. Finally, Needham & Company LLC increased their price target on CorMedix from $12.00 to $14.00 and gave the stock a “buy” rating in a research note on Tuesday. Eight analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $15.22.

CorMedix Price Performance

Shares of NASDAQ:CRMD opened at $4.66 on Friday. The firm’s 50 day moving average is $7.18 and its two-hundred day moving average is $7.57. CorMedix has a 52 week low of $4.65 and a 52 week high of $13.02. The firm has a market capitalization of $363.20 million, a P/E ratio of 6.75, a PEG ratio of 0.90 and a beta of 1.48. The company has a current ratio of 2.56, a quick ratio of 2.36 and a debt-to-equity ratio of 0.31.

CorMedix (NASDAQ:CRMD) last released its quarterly earnings results on Thursday, November 12th. The company reported ($0.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.07). The business had revenue of $54.52 million for the quarter, compared to the consensus estimate of $51.76 million. CorMedix had a net margin of 15.49% and a return on equity of 27.12%. Analysts anticipate that CorMedix will post 0.54 earnings per share for the current year.

Institutional Trading of CorMedix

Institutional investors have recently made changes to their positions in the stock. Gryphon Financial Partners LLC raised its position in shares of CorMedix by 6.3% during the first quarter. Gryphon Financial Partners LLC now owns 27,401 shares of the company’s stock worth $186,000 after purchasing an additional 1,618 shares during the period. China Universal Asset Management Co. Ltd. lifted its holdings in shares of CorMedix by 13.9% during the third quarter. China Universal Asset Management Co. Ltd. now owns 14,222 shares of the company’s stock valued at $113,000 after purchasing an additional 1,736 shares during the last quarter. HighTower Advisors LLC boosted its position in shares of CorMedix by 8.2% in the 2nd quarter. HighTower Advisors LLC now owns 32,655 shares of the company’s stock valued at $256,000 after purchasing an additional 2,476 shares during the period. Sigma Planning Corp boosted its position in shares of CorMedix by 8.5% in the 3rd quarter. Sigma Planning Corp now owns 32,142 shares of the company’s stock valued at $247,000 after purchasing an additional 2,531 shares during the period. Finally, Advisors Asset Management Inc. acquired a new position in shares of CorMedix in the 3rd quarter valued at $26,000. 34.18% of the stock is owned by institutional investors and hedge funds.

Recent CorMedix Headlines

These are some of the CRMD headlines that stood out recently:

• Positive Sentiment: CorMedix reported third-quarter revenue of $54.5 million, above the roughly $51.8 million analyst estimate, and adjusted EBITDA of $3.1 million. The company maintained its 2026 revenue outlook and narrowed its adjusted EBITDA guidance. CorMedix third-quarter results and business update
• Positive Sentiment: The planned Heron asset acquisition could add an estimated $125 million–$150 million in pro forma 2027 revenue, with management targeting $45 million–$60 million in annual synergies. Heron assets and synergy outlook
• Negative Sentiment: DefenCath pricing pressure is weighing on sales expectations, despite the quarterly revenue beat. CorMedix reported a $14.7 million net loss, and coverage described the earnings result as disappointing; progress with Rezzayo and the Heron transaction are part of the company’s longer-term outlook. Zacks coverage of quarterly results and pricing pressure

CorMedix Company Profile

CorMedix Inc. is a biopharmaceutical company focused on products for infectious and inflammatory diseases. Its lead product, DefenCath, is an antimicrobial catheter-lock solution containing taurolidine and heparin. The U.S. Food and Drug Administration approved it to reduce catheter-related bloodstream infections in adults with kidney failure who receive chronic hemodialysis through a central venous catheter. CorMedix expanded its business in 2024 by acquiring Melinta Therapeutics, adding marketed antibiotics to its portfolio.